Eli Lilly antibody cuts covid-19 risk up to 80% in nursing home study
Riley Griffin, Bloomberg
FacebookTwitterEmail
Eli Lilly corporate headquarters in Indianapolis. Eli Lilly continues to back a potential COVID-19 treatment despite research showing that it may not work on hospitalized patients. The drugmaker said Tuesday, Oct. 27, 2020, that It remains confident that its drug may stop COVID from developing in other patients.Darron Cummings/Associated Press
Eli Lilly s antibody therapy reduced nursing home residents risk of symptomatic Covid-19 by as much as 80% when used preventively in a study.
The infused treatment, cleared for use in high-risk Covid patients with mild-to-moderate disease who haven t been hospitalized, also significantly reduced the risk of symptomatic disease in nursing home workers, according to a statement from Lilly on Thursday.